Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions
Marginal Zone B-cell Lymphoma
Interventions
DRUG

bendamustine plus rituximab

Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle

Trial Locations (11)

54907

Chonbuk National University Hospital, Jeonju

Unknown

Hallym University Medical Center, Anyang-si

Chungnam National University, Daejeon

Gachon University Gil Medical Center, Incheon

Gyeongsang National University Hospital, Jinju

Seoul National University Bundang Hospital, Seongnam

Inje Universit, Seoul

Korea Cancer Center Hospital, Seoul

Seoul National University Boramae Hospital, Seoul

Seoul National University Hospital, Seoul

The Catholic University of Korea, Seoul

All Listed Sponsors
collaborator

Gyeongsang National University Hospital

OTHER

collaborator

Korea Cancer Center Hospital

OTHER

collaborator

Seoul National University Boramae Hospital

OTHER

collaborator

Hallym University Medical Center

OTHER

collaborator

Inje University

OTHER

collaborator

Gangnam Severance Hospital

OTHER

collaborator

Chonbuk National University Hospital

OTHER

collaborator

Chungnam National University

OTHER

collaborator

The Catholic University of Korea

OTHER

collaborator

Wonju Severance Christian Hospital

OTHER

collaborator

Gachon University Gil Medical Center

OTHER

collaborator

Seoul National University Bundang Hospital

OTHER

lead

Seoul National University Hospital

OTHER

NCT02433795 - Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) | Biotech Hunter | Biotech Hunter